This company has been marked as potentially delisted and may not be actively trading. Travere Therapeutics (RTRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock RTRX vs. AKRO, MRUS, MOR, PTGX, CRNX, OGN, CPRX, VKTX, XENE, and MLTXShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Akero Therapeutics (AKRO), Merus (MRUS), MorphoSys (MOR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), Organon & Co. (OGN), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Xenon Pharmaceuticals (XENE), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "medical" sector. Travere Therapeutics vs. Akero Therapeutics Merus MorphoSys Protagonist Therapeutics Crinetics Pharmaceuticals Organon & Co. Catalyst Pharmaceuticals Viking Therapeutics Xenon Pharmaceuticals MoonLake Immunotherapeutics Travere Therapeutics (NASDAQ:RTRX) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, community ranking, analyst recommendations, earnings and institutional ownership. Does the media favor RTRX or AKRO? In the previous week, Akero Therapeutics had 7 more articles in the media than Travere Therapeutics. MarketBeat recorded 7 mentions for Akero Therapeutics and 0 mentions for Travere Therapeutics. Akero Therapeutics' average media sentiment score of 1.02 beat Travere Therapeutics' score of 0.00 indicating that Akero Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Travere Therapeutics Neutral Akero Therapeutics Positive Does the MarketBeat Community prefer RTRX or AKRO? Travere Therapeutics received 303 more outperform votes than Akero Therapeutics when rated by MarketBeat users. Likewise, 73.17% of users gave Travere Therapeutics an outperform vote while only 65.36% of users gave Akero Therapeutics an outperform vote. CompanyUnderperformOutperformTravere TherapeuticsOutperform Votes42073.17% Underperform Votes15426.83% Akero TherapeuticsOutperform Votes11765.36% Underperform Votes6234.64% Is RTRX or AKRO more profitable? Akero Therapeutics has a net margin of 0.00% compared to Travere Therapeutics' net margin of -49.13%. Akero Therapeutics' return on equity of -32.46% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Travere Therapeutics-49.13% -36.38% -14.90% Akero Therapeutics N/A -32.46%-29.83% Which has better valuation & earnings, RTRX or AKRO? Travere Therapeutics has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTravere Therapeutics$175.34M5.34-$146.43M-$3.46-5.30Akero TherapeuticsN/AN/A-$151.76M-$3.75-10.93 Which has more volatility and risk, RTRX or AKRO? Travere Therapeutics has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.18, suggesting that its stock price is 118% less volatile than the S&P 500. Do analysts rate RTRX or AKRO? Akero Therapeutics has a consensus price target of $76.29, suggesting a potential upside of 86.06%. Given Akero Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Akero Therapeutics is more favorable than Travere Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Travere Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryTravere Therapeutics beats Akero Therapeutics on 8 of the 15 factors compared between the two stocks. Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTRX vs. The Competition Export to ExcelMetricTravere TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$935.78M$6.68B$5.44B$7.80BDividend YieldN/A3.17%5.43%4.30%P/E Ratio-8.697.1422.1418.40Price / Sales5.34238.89389.71101.29Price / CashN/A65.6738.2034.62Price / Book3.566.266.664.18Net Income-$146.43M$142.48M$3.21B$247.71M Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTRXTravere TherapeuticsN/A$18.33+4.0%N/A+227.1%$935.78M$175.34M-8.69221High Trading VolumeAKROAkero Therapeutics4.0991 of 5 stars$37.67+0.1%$76.29+102.5%+116.6%$3.00BN/A-10.0530Positive NewsGap UpMRUSMerus3.1927 of 5 stars$43.23+0.4%$85.31+97.3%-3.0%$2.99B$36.13M-10.9437Positive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730PTGXProtagonist Therapeutics3.8226 of 5 stars$45.80-1.0%$65.44+42.9%+80.4%$2.81B$434.43M17.22120News CoveragePositive NewsCRNXCrinetics Pharmaceuticals3.6145 of 5 stars$30.15-0.9%$73.00+142.1%-23.4%$2.81B$1.04M-8.08210News CoveragePositive NewsOGNOrganon & Co.4.8395 of 5 stars$10.67-4.0%$20.60+93.1%-33.7%$2.75B$6.40B3.2010,000Upcoming EarningsPositive NewsCPRXCatalyst Pharmaceuticals4.6075 of 5 stars$22.02-2.2%$32.29+46.6%+59.7%$2.69B$491.73M18.6680Positive NewsVKTXViking Therapeutics4.212 of 5 stars$23.72-0.9%$89.75+278.4%-63.7%$2.66BN/A-23.7220Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageXENEXenon Pharmaceuticals2.8105 of 5 stars$34.70-1.2%$56.78+63.6%-6.2%$2.66B$9.43M-12.30210Analyst UpgradeNews CoveragePositive NewsMLTXMoonLake Immunotherapeutics2.0071 of 5 stars$40.00+4.4%$80.50+101.3%-6.7%$2.56BN/A-31.012News Coverage Related Companies and Tools Related Companies Akero Therapeutics Alternatives Merus Alternatives MorphoSys Alternatives Protagonist Therapeutics Alternatives Crinetics Pharmaceuticals Alternatives Organon & Co. Alternatives Catalyst Pharmaceuticals Alternatives Viking Therapeutics Alternatives Xenon Pharmaceuticals Alternatives MoonLake Immunotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RTRX) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RTRX Stock Free RTRX Stock Alerts